Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Medicinal Cannabis Testing Market

ID: MRFR/HC/41728-HCR
111 Pages
Rahul Gotadki
Last Updated: April 15, 2026

Medicinal Cannabis Testing Market Research Report: Size, Share, Trend Analysis By Types of Testing (Cannabinoid Profiling,contaminant Testing, Pesticide Residue Testing, Microbial Testing), By Sample Type (Flower, Concentrates, Edibles, Oils), By End Use (Research Laboratories, Pharmaceutical Companies, Agriculture), By Methodology (Chromatography, Mass Spectrometry, Immunoassay) andBy Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Medicinal Cannabis Testing Market Infographic
Purchase Options
  1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
    1. 1.1 EXECUTIVE SUMMARY | |
      1. 1.1.1 Market Overview | |
      2. 1.1.2 Key Findings | |
      3. 1.1.3 Market Segmentation | |
      4. 1.1.4 Competitive Landscape | |
      5. 1.1.5 Challenges and Opportunities | |
      6. 1.1.6 Future Outlook 2
  2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
    1. 2.1 MARKET INTRODUCTION | |
      1. 2.1.1 Definition | |
      2. 2.1.2 Scope of the study | | |
        1. 2.1.2.1 Research Objective | | |
        2. 2.1.2.2 Assumption | | |
        3. 2.1.2.3 Limitations |
    2. 2.2 RESEARCH METHODOLOGY | |
      1. 2.2.1 Overview | |
      2. 2.2.2 Data Mining | |
      3. 2.2.3 Secondary Research | |
      4. 2.2.4 Primary Research | | |
        1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
        2. 2.2.4.2 Breakdown of Primary Respondents | |
      5. 2.2.5 Forecasting Model | |
      6. 2.2.6 Market Size Estimation | | |
        1. 2.2.6.1 Bottom-Up Approach | | |
        2. 2.2.6.2 Top-Down Approach | |
      7. 2.2.7 Data Triangulation | |
      8. 2.2.8 Validation 3
  3. SECTION III: QUALITATIVE ANALYSIS |
    1. 3.1 MARKET DYNAMICS | |
      1. 3.1.1 Overview | |
      2. 3.1.2 Drivers | |
      3. 3.1.3 Restraints | |
      4. 3.1.4 Opportunities |
    2. 3.2 MARKET FACTOR ANALYSIS | |
      1. 3.2.1 Value chain Analysis | |
      2. 3.2.2 Porter's Five Forces Analysis | | |
        1. 3.2.2.1 Bargaining Power of Suppliers | | |
        2. 3.2.2.2 Bargaining Power of Buyers | | |
        3. 3.2.2.3 Threat of New Entrants | | |
        4. 3.2.2.4 Threat of Substitutes | | |
        5. 3.2.2.5 Intensity of Rivalry | |
      3. 3.2.3 COVID-19 Impact Analysis | | |
        1. 3.2.3.1 Market Impact Analysis | | |
        2. 3.2.3.2 Regional Impact | | |
        3. 3.2.3.3 Opportunity and Threat Analysis 4
  4. SECTION IV: QUANTITATIVE ANALYSIS |
    1. 4.1 Healthcare, BY Type of Testing (USD Billion) | |
      1. 4.1.1 Cannabinoid Profiling | |
      2. 4.1.2 Contaminant Testing | |
      3. 4.1.3 Pesticide Residue Testing | |
      4. 4.1.4 Microbial Testing |
    2. 4.2 Healthcare, BY Sample Type (USD Billion) | |
      1. 4.2.1 Flower | |
      2. 4.2.2 Concentrates | |
      3. 4.2.3 Edibles | |
      4. 4.2.4 Oils |
    3. 4.3 Healthcare, BY End Use (USD Billion) | |
      1. 4.3.1 Research Laboratories | |
      2. 4.3.2 Pharmaceutical Companies | |
      3. 4.3.3 Agriculture |
    4. 4.4 Healthcare, BY Methodology (USD Billion) | |
      1. 4.4.1 Chromatography | |
      2. 4.4.2 Mass Spectrometry | |
      3. 4.4.3 Immunoassay |
    5. 4.5 Healthcare, BY Region (USD Billion) | |
      1. 4.5.1 North America | | |
        1. 4.5.1.1 US | | |
        2. 4.5.1.2 Canada | |
      2. 4.5.2 Europe | | |
        1. 4.5.2.1 Germany | | |
        2. 4.5.2.2 UK | | |
        3. 4.5.2.3 France | | |
        4. 4.5.2.4 Russia | | |
        5. 4.5.2.5 Italy | | |
        6. 4.5.2.6 Spain | | |
        7. 4.5.2.7 Rest of Europe | |
      3. 4.5.3 APAC | | |
        1. 4.5.3.1 China | | |
        2. 4.5.3.2 India | | |
        3. 4.5.3.3 Japan | | |
        4. 4.5.3.4 South Korea | | |
        5. 4.5.3.5 Malaysia | | |
        6. 4.5.3.6 Thailand | | |
        7. 4.5.3.7 Indonesia | | |
        8. 4.5.3.8 Rest of APAC | |
      4. 4.5.4 South America | | |
        1. 4.5.4.1 Brazil | | |
        2. 4.5.4.2 Mexico | | |
        3. 4.5.4.3 Argentina | | |
        4. 4.5.4.4 Rest of South America | |
      5. 4.5.5 MEA | | |
        1. 4.5.5.1 GCC Countries | | |
        2. 4.5.5.2 South Africa | | |
        3. 4.5.5.3 Rest of MEA 5
  5. SECTION V: COMPETITIVE ANALYSIS |
    1. 5.1 Competitive Landscape | |
      1. 5.1.1 Overview | |
      2. 5.1.2 Competitive Analysis | |
      3. 5.1.3 Market share Analysis | |
      4. 5.1.4 Major Growth Strategy in the Healthcare | |
      5. 5.1.5 Competitive Benchmarking | |
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
      7. 5.1.7 Key developments and growth strategies | | |
        1. 5.1.7.1 New Product Launch/Service Deployment | | |
        2. 5.1.7.2 Merger & Acquisitions | | |
        3. 5.1.7.3 Joint Ventures | |
      8. 5.1.8 Major Players Financial Matrix | | |
        1. 5.1.8.1 Sales and Operating Income | | |
        2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
    2. 5.2 Company Profiles | |
      1. 5.2.1 SC Labs (US) | | |
        1. 5.2.1.1 Financial Overview | | |
        2. 5.2.1.2 Products Offered | | |
        3. 5.2.1.3 Key Developments | | |
        4. 5.2.1.4 SWOT Analysis | | |
        5. 5.2.1.5 Key Strategies | |
      2. 5.2.2 Steep Hill (US) | | |
        1. 5.2.2.1 Financial Overview | | |
        2. 5.2.2.2 Products Offered | | |
        3. 5.2.2.3 Key Developments | | |
        4. 5.2.2.4 SWOT Analysis | | |
        5. 5.2.2.5 Key Strategies | |
      3. 5.2.3 Eurofins Scientific (FR) | | |
        1. 5.2.3.1 Financial Overview | | |
        2. 5.2.3.2 Products Offered | | |
        3. 5.2.3.3 Key Developments | | |
        4. 5.2.3.4 SWOT Analysis | | |
        5. 5.2.3.5 Key Strategies | |
      4. 5.2.4 PharmaCann (US) | | |
        1. 5.2.4.1 Financial Overview | | |
        2. 5.2.4.2 Products Offered | | |
        3. 5.2.4.3 Key Developments | | |
        4. 5.2.4.4 SWOT Analysis | | |
        5. 5.2.4.5 Key Strategies | |
      5. 5.2.5 Cannalysis (US) | | |
        1. 5.2.5.1 Financial Overview | | |
        2. 5.2.5.2 Products Offered | | |
        3. 5.2.5.3 Key Developments | | |
        4. 5.2.5.4 SWOT Analysis | | |
        5. 5.2.5.5 Key Strategies | |
      6. 5.2.6 CannaSafe (US) | | |
        1. 5.2.6.1 Financial Overview | | |
        2. 5.2.6.2 Products Offered | | |
        3. 5.2.6.3 Key Developments | | |
        4. 5.2.6.4 SWOT Analysis | | |
        5. 5.2.6.5 Key Strategies | |
      7. 5.2.7 MCR Labs (US) | | |
        1. 5.2.7.1 Financial Overview | | |
        2. 5.2.7.2 Products Offered | | |
        3. 5.2.7.3 Key Developments | | |
        4. 5.2.7.4 SWOT Analysis | | |
        5. 5.2.7.5 Key Strategies | |
      8. 5.2.8 Bureau Veritas (FR) | | |
        1. 5.2.8.1 Financial Overview | | |
        2. 5.2.8.2 Products Offered | | |
        3. 5.2.8.3 Key Developments | | |
        4. 5.2.8.4 SWOT Analysis | | |
        5. 5.2.8.5 Key Strategies | |
      9. 5.2.9 CannaIQ (US) | | |
        1. 5.2.9.1 Financial Overview | | |
        2. 5.2.9.2 Products Offered | | |
        3. 5.2.9.3 Key Developments | | |
        4. 5.2.9.4 SWOT Analysis | | |
        5. 5.2.9.5 Key Strategies |
    3. 5.3 Appendix | |
      1. 5.3.1 References | |
      2. 5.3.2 Related Reports 6 LIST OF FIGURES |
    4. 6.1 MARKET SYNOPSIS |
    5. 6.2 NORTH AMERICA MARKET ANALYSIS |
    6. 6.3 US MARKET ANALYSIS BY TYPE OF TESTING |
    7. 6.4 US MARKET ANALYSIS BY SAMPLE TYPE |
    8. 6.5 US MARKET ANALYSIS BY END USE |
    9. 6.6 US MARKET ANALYSIS BY METHODOLOGY |
    10. 6.7 CANADA MARKET ANALYSIS BY TYPE OF TESTING |
    11. 6.8 CANADA MARKET ANALYSIS BY SAMPLE TYPE |
    12. 6.9 CANADA MARKET ANALYSIS BY END USE |
    13. 6.10 CANADA MARKET ANALYSIS BY METHODOLOGY |
    14. 6.11 EUROPE MARKET ANALYSIS |
    15. 6.12 GERMANY MARKET ANALYSIS BY TYPE OF TESTING |
    16. 6.13 GERMANY MARKET ANALYSIS BY SAMPLE TYPE |
    17. 6.14 GERMANY MARKET ANALYSIS BY END USE |
    18. 6.15 GERMANY MARKET ANALYSIS BY METHODOLOGY |
    19. 6.16 UK MARKET ANALYSIS BY TYPE OF TESTING |
    20. 6.17 UK MARKET ANALYSIS BY SAMPLE TYPE |
    21. 6.18 UK MARKET ANALYSIS BY END USE |
    22. 6.19 UK MARKET ANALYSIS BY METHODOLOGY |
    23. 6.20 FRANCE MARKET ANALYSIS BY TYPE OF TESTING |
    24. 6.21 FRANCE MARKET ANALYSIS BY SAMPLE TYPE |
    25. 6.22 FRANCE MARKET ANALYSIS BY END USE |
    26. 6.23 FRANCE MARKET ANALYSIS BY METHODOLOGY |
    27. 6.24 RUSSIA MARKET ANALYSIS BY TYPE OF TESTING |
    28. 6.25 RUSSIA MARKET ANALYSIS BY SAMPLE TYPE |
    29. 6.26 RUSSIA MARKET ANALYSIS BY END USE |
    30. 6.27 RUSSIA MARKET ANALYSIS BY METHODOLOGY |
    31. 6.28 ITALY MARKET ANALYSIS BY TYPE OF TESTING |
    32. 6.29 ITALY MARKET ANALYSIS BY SAMPLE TYPE |
    33. 6.30 ITALY MARKET ANALYSIS BY END USE |
    34. 6.31 ITALY MARKET ANALYSIS BY METHODOLOGY |
    35. 6.32 SPAIN MARKET ANALYSIS BY TYPE OF TESTING |
    36. 6.33 SPAIN MARKET ANALYSIS BY SAMPLE TYPE |
    37. 6.34 SPAIN MARKET ANALYSIS BY END USE |
    38. 6.35 SPAIN MARKET ANALYSIS BY METHODOLOGY |
    39. 6.36 REST OF EUROPE MARKET ANALYSIS BY TYPE OF TESTING |
    40. 6.37 REST OF EUROPE MARKET ANALYSIS BY SAMPLE TYPE |
    41. 6.38 REST OF EUROPE MARKET ANALYSIS BY END USE |
    42. 6.39 REST OF EUROPE MARKET ANALYSIS BY METHODOLOGY |
    43. 6.40 APAC MARKET ANALYSIS |
    44. 6.41 CHINA MARKET ANALYSIS BY TYPE OF TESTING |
    45. 6.42 CHINA MARKET ANALYSIS BY SAMPLE TYPE |
    46. 6.43 CHINA MARKET ANALYSIS BY END USE |
    47. 6.44 CHINA MARKET ANALYSIS BY METHODOLOGY |
    48. 6.45 INDIA MARKET ANALYSIS BY TYPE OF TESTING |
    49. 6.46 INDIA MARKET ANALYSIS BY SAMPLE TYPE |
    50. 6.47 INDIA MARKET ANALYSIS BY END USE |
    51. 6.48 INDIA MARKET ANALYSIS BY METHODOLOGY |
    52. 6.49 JAPAN MARKET ANALYSIS BY TYPE OF TESTING |
    53. 6.50 JAPAN MARKET ANALYSIS BY SAMPLE TYPE |
    54. 6.51 JAPAN MARKET ANALYSIS BY END USE |
    55. 6.52 JAPAN MARKET ANALYSIS BY METHODOLOGY |
    56. 6.53 SOUTH KOREA MARKET ANALYSIS BY TYPE OF TESTING |
    57. 6.54 SOUTH KOREA MARKET ANALYSIS BY SAMPLE TYPE |
    58. 6.55 SOUTH KOREA MARKET ANALYSIS BY END USE |
    59. 6.56 SOUTH KOREA MARKET ANALYSIS BY METHODOLOGY |
    60. 6.57 MALAYSIA MARKET ANALYSIS BY TYPE OF TESTING |
    61. 6.58 MALAYSIA MARKET ANALYSIS BY SAMPLE TYPE |
    62. 6.59 MALAYSIA MARKET ANALYSIS BY END USE |
    63. 6.60 MALAYSIA MARKET ANALYSIS BY METHODOLOGY |
    64. 6.61 THAILAND MARKET ANALYSIS BY TYPE OF TESTING |
    65. 6.62 THAILAND MARKET ANALYSIS BY SAMPLE TYPE |
    66. 6.63 THAILAND MARKET ANALYSIS BY END USE |
    67. 6.64 THAILAND MARKET ANALYSIS BY METHODOLOGY |
    68. 6.65 INDONESIA MARKET ANALYSIS BY TYPE OF TESTING |
    69. 6.66 INDONESIA MARKET ANALYSIS BY SAMPLE TYPE |
    70. 6.67 INDONESIA MARKET ANALYSIS BY END USE |
    71. 6.68 INDONESIA MARKET ANALYSIS BY METHODOLOGY |
    72. 6.69 REST OF APAC MARKET ANALYSIS BY TYPE OF TESTING |
    73. 6.70 REST OF APAC MARKET ANALYSIS BY SAMPLE TYPE |
    74. 6.71 REST OF APAC MARKET ANALYSIS BY END USE |
    75. 6.72 REST OF APAC MARKET ANALYSIS BY METHODOLOGY |
    76. 6.73 SOUTH AMERICA MARKET ANALYSIS |
    77. 6.74 BRAZIL MARKET ANALYSIS BY TYPE OF TESTING |
    78. 6.75 BRAZIL MARKET ANALYSIS BY SAMPLE TYPE |
    79. 6.76 BRAZIL MARKET ANALYSIS BY END USE |
    80. 6.77 BRAZIL MARKET ANALYSIS BY METHODOLOGY |
    81. 6.78 MEXICO MARKET ANALYSIS BY TYPE OF TESTING |
    82. 6.79 MEXICO MARKET ANALYSIS BY SAMPLE TYPE |
    83. 6.80 MEXICO MARKET ANALYSIS BY END USE |
    84. 6.81 MEXICO MARKET ANALYSIS BY METHODOLOGY |
    85. 6.82 ARGENTINA MARKET ANALYSIS BY TYPE OF TESTING |
    86. 6.83 ARGENTINA MARKET ANALYSIS BY SAMPLE TYPE |
    87. 6.84 ARGENTINA MARKET ANALYSIS BY END USE |
    88. 6.85 ARGENTINA MARKET ANALYSIS BY METHODOLOGY |
    89. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE OF TESTING |
    90. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY SAMPLE TYPE |
    91. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USE |
    92. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY METHODOLOGY |
    93. 6.90 MEA MARKET ANALYSIS |
    94. 6.91 GCC COUNTRIES MARKET ANALYSIS BY TYPE OF TESTING |
    95. 6.92 GCC COUNTRIES MARKET ANALYSIS BY SAMPLE TYPE |
    96. 6.93 GCC COUNTRIES MARKET ANALYSIS BY END USE |
    97. 6.94 GCC COUNTRIES MARKET ANALYSIS BY METHODOLOGY |
    98. 6.95 SOUTH AFRICA MARKET ANALYSIS BY TYPE OF TESTING |
    99. 6.96 SOUTH AFRICA MARKET ANALYSIS BY SAMPLE TYPE |
    100. 6.97 SOUTH AFRICA MARKET ANALYSIS BY END USE |
    101. 6.98 SOUTH AFRICA MARKET ANALYSIS BY METHODOLOGY |
    102. 6.99 REST OF MEA MARKET ANALYSIS BY TYPE OF TESTING |
    103. 6.100 REST OF MEA MARKET ANALYSIS BY SAMPLE TYPE |
    104. 6.101 REST OF MEA MARKET ANALYSIS BY END USE |
    105. 6.102 REST OF MEA MARKET ANALYSIS BY METHODOLOGY |
    106. 6.103 KEY BUYING CRITERIA OF HEALTHCARE |
    107. 6.104 RESEARCH PROCESS OF MRFR |
    108. 6.105 DRO ANALYSIS OF HEALTHCARE |
    109. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
    110. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
    111. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE |
    112. 6.109 HEALTHCARE, BY TYPE OF TESTING, 2024 (% SHARE) |
    113. 6.110 HEALTHCARE, BY TYPE OF TESTING, 2024 TO 2035 (USD Billion) |
    114. 6.111 HEALTHCARE, BY SAMPLE TYPE, 2024 (% SHARE) |
    115. 6.112 HEALTHCARE, BY SAMPLE TYPE, 2024 TO 2035 (USD Billion) |
    116. 6.113 HEALTHCARE, BY END USE, 2024 (% SHARE) |
    117. 6.114 HEALTHCARE, BY END USE, 2024 TO 2035 (USD Billion) |
    118. 6.115 HEALTHCARE, BY METHODOLOGY, 2024 (% SHARE) |
    119. 6.116 HEALTHCARE, BY METHODOLOGY, 2024 TO 2035 (USD Billion) |
    120. 6.117 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
    121. 7.1 LIST OF ASSUMPTIONS | |
      1. 7.1.1 |
    122. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.2.1 BY TYPE OF TESTING, 2025-2035 (USD Billion) | |
      2. 7.2.2 BY SAMPLE TYPE, 2025-2035 (USD Billion) | |
      3. 7.2.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.2.4 BY METHODOLOGY, 2025-2035 (USD Billion) |
    123. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.3.1 BY TYPE OF TESTING, 2025-2035 (USD Billion) | |
      2. 7.3.2 BY SAMPLE TYPE, 2025-2035 (USD Billion) | |
      3. 7.3.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.3.4 BY METHODOLOGY, 2025-2035 (USD Billion) |
    124. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.4.1 BY TYPE OF TESTING, 2025-2035 (USD Billion) | |
      2. 7.4.2 BY SAMPLE TYPE, 2025-2035 (USD Billion) | |
      3. 7.4.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.4.4 BY METHODOLOGY, 2025-2035 (USD Billion) |
    125. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.5.1 BY TYPE OF TESTING, 2025-2035 (USD Billion) | |
      2. 7.5.2 BY SAMPLE TYPE, 2025-2035 (USD Billion) | |
      3. 7.5.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.5.4 BY METHODOLOGY, 2025-2035 (USD Billion) |
    126. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.6.1 BY TYPE OF TESTING, 2025-2035 (USD Billion) | |
      2. 7.6.2 BY SAMPLE TYPE, 2025-2035 (USD Billion) | |
      3. 7.6.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.6.4 BY METHODOLOGY, 2025-2035 (USD Billion) |
    127. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.7.1 BY TYPE OF TESTING, 2025-2035 (USD Billion) | |
      2. 7.7.2 BY SAMPLE TYPE, 2025-2035 (USD Billion) | |
      3. 7.7.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.7.4 BY METHODOLOGY, 2025-2035 (USD Billion) |
    128. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.8.1 BY TYPE OF TESTING, 2025-2035 (USD Billion) | |
      2. 7.8.2 BY SAMPLE TYPE, 2025-2035 (USD Billion) | |
      3. 7.8.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.8.4 BY METHODOLOGY, 2025-2035 (USD Billion) |
    129. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.9.1 BY TYPE OF TESTING, 2025-2035 (USD Billion) | |
      2. 7.9.2 BY SAMPLE TYPE, 2025-2035 (USD Billion) | |
      3. 7.9.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.9.4 BY METHODOLOGY, 2025-2035 (USD Billion) |
    130. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.10.1 BY TYPE OF TESTING, 2025-2035 (USD Billion) | |
      2. 7.10.2 BY SAMPLE TYPE, 2025-2035 (USD Billion) | |
      3. 7.10.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.10.4 BY METHODOLOGY, 2025-2035 (USD Billion) |
    131. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.11.1 BY TYPE OF TESTING, 2025-2035 (USD Billion) | |
      2. 7.11.2 BY SAMPLE TYPE, 2025-2035 (USD Billion) | |
      3. 7.11.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.11.4 BY METHODOLOGY, 2025-2035 (USD Billion) |
    132. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.12.1 BY TYPE OF TESTING, 2025-2035 (USD Billion) | |
      2. 7.12.2 BY SAMPLE TYPE, 2025-2035 (USD Billion) | |
      3. 7.12.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.12.4 BY METHODOLOGY, 2025-2035 (USD Billion) |
    133. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.13.1 BY TYPE OF TESTING, 2025-2035 (USD Billion) | |
      2. 7.13.2 BY SAMPLE TYPE, 2025-2035 (USD Billion) | |
      3. 7.13.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.13.4 BY METHODOLOGY, 2025-2035 (USD Billion) |
    134. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.14.1 BY TYPE OF TESTING, 2025-2035 (USD Billion) | |
      2. 7.14.2 BY SAMPLE TYPE, 2025-2035 (USD Billion) | |
      3. 7.14.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.14.4 BY METHODOLOGY, 2025-2035 (USD Billion) |
    135. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.15.1 BY TYPE OF TESTING, 2025-2035 (USD Billion) | |
      2. 7.15.2 BY SAMPLE TYPE, 2025-2035 (USD Billion) | |
      3. 7.15.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.15.4 BY METHODOLOGY, 2025-2035 (USD Billion) |
    136. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.16.1 BY TYPE OF TESTING, 2025-2035 (USD Billion) | |
      2. 7.16.2 BY SAMPLE TYPE, 2025-2035 (USD Billion) | |
      3. 7.16.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.16.4 BY METHODOLOGY, 2025-2035 (USD Billion) |
    137. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.17.1 BY TYPE OF TESTING, 2025-2035 (USD Billion) | |
      2. 7.17.2 BY SAMPLE TYPE, 2025-2035 (USD Billion) | |
      3. 7.17.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.17.4 BY METHODOLOGY, 2025-2035 (USD Billion) |
    138. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.18.1 BY TYPE OF TESTING, 2025-2035 (USD Billion) | |
      2. 7.18.2 BY SAMPLE TYPE, 2025-2035 (USD Billion) | |
      3. 7.18.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.18.4 BY METHODOLOGY, 2025-2035 (USD Billion) |
    139. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.19.1 BY TYPE OF TESTING, 2025-2035 (USD Billion) | |
      2. 7.19.2 BY SAMPLE TYPE, 2025-2035 (USD Billion) | |
      3. 7.19.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.19.4 BY METHODOLOGY, 2025-2035 (USD Billion) |
    140. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.20.1 BY TYPE OF TESTING, 2025-2035 (USD Billion) | |
      2. 7.20.2 BY SAMPLE TYPE, 2025-2035 (USD Billion) | |
      3. 7.20.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.20.4 BY METHODOLOGY, 2025-2035 (USD Billion) |
    141. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.21.1 BY TYPE OF TESTING, 2025-2035 (USD Billion) | |
      2. 7.21.2 BY SAMPLE TYPE, 2025-2035 (USD Billion) | |
      3. 7.21.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.21.4 BY METHODOLOGY, 2025-2035 (USD Billion) |
    142. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.22.1 BY TYPE OF TESTING, 2025-2035 (USD Billion) | |
      2. 7.22.2 BY SAMPLE TYPE, 2025-2035 (USD Billion) | |
      3. 7.22.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.22.4 BY METHODOLOGY, 2025-2035 (USD Billion) |
    143. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.23.1 BY TYPE OF TESTING, 2025-2035 (USD Billion) | |
      2. 7.23.2 BY SAMPLE TYPE, 2025-2035 (USD Billion) | |
      3. 7.23.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.23.4 BY METHODOLOGY, 2025-2035 (USD Billion) |
    144. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.24.1 BY TYPE OF TESTING, 2025-2035 (USD Billion) | |
      2. 7.24.2 BY SAMPLE TYPE, 2025-2035 (USD Billion) | |
      3. 7.24.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.24.4 BY METHODOLOGY, 2025-2035 (USD Billion) |
    145. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.25.1 BY TYPE OF TESTING, 2025-2035 (USD Billion) | |
      2. 7.25.2 BY SAMPLE TYPE, 2025-2035 (USD Billion) | |
      3. 7.25.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.25.4 BY METHODOLOGY, 2025-2035 (USD Billion) |
    146. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.26.1 BY TYPE OF TESTING, 2025-2035 (USD Billion) | |
      2. 7.26.2 BY SAMPLE TYPE, 2025-2035 (USD Billion) | |
      3. 7.26.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.26.4 BY METHODOLOGY, 2025-2035 (USD Billion) |
    147. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.27.1 BY TYPE OF TESTING, 2025-2035 (USD Billion) | |
      2. 7.27.2 BY SAMPLE TYPE, 2025-2035 (USD Billion) | |
      3. 7.27.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.27.4 BY METHODOLOGY, 2025-2035 (USD Billion) |
    148. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.28.1 BY TYPE OF TESTING, 2025-2035 (USD Billion) | |
      2. 7.28.2 BY SAMPLE TYPE, 2025-2035 (USD Billion) | |
      3. 7.28.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.28.4 BY METHODOLOGY, 2025-2035 (USD Billion) |
    149. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.29.1 BY TYPE OF TESTING, 2025-2035 (USD Billion) | |
      2. 7.29.2 BY SAMPLE TYPE, 2025-2035 (USD Billion) | |
      3. 7.29.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.29.4 BY METHODOLOGY, 2025-2035 (USD Billion) |
    150. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.30.1 BY TYPE OF TESTING, 2025-2035 (USD Billion) | |
      2. 7.30.2 BY SAMPLE TYPE, 2025-2035 (USD Billion) | |
      3. 7.30.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.30.4 BY METHODOLOGY, 2025-2035 (USD Billion) |
    151. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
      1. 7.31.1 |
    152. 7.32 ACQUISITION/PARTNERSHIP | |

Healthcare Market Segmentation

Healthcare By Type of Testing (USD Billion, 2025-2035)

  • Cannabinoid Profiling
  • Contaminant Testing
  • Pesticide Residue Testing
  • Microbial Testing

Healthcare By Sample Type (USD Billion, 2025-2035)

  • Flower
  • Concentrates
  • Edibles
  • Oils

Healthcare By End Use (USD Billion, 2025-2035)

  • Research Laboratories
  • Pharmaceutical Companies
  • Agriculture

Healthcare By Methodology (USD Billion, 2025-2035)

  • Chromatography
  • Mass Spectrometry
  • Immunoassay

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions